Interleukin-6 involvement in mesothelioma pathobiology: inhibition by interferon ? immunotherapy
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
A role for interleukin-6 (IL-6) in malignant mesothelioma has been suggested by the clinically presenting symptoms of mesothelioma patients, which include fever, weight loss and thrombocytosis. A murine model of malignant mesothelioma was therefore used to examine the potential role of IL-6 in this cancer type and whether the effect of interferon alpha (IFN alpha) therapy on mesothelioma might be mediated, in part, by regulating IL-6 levels and/or IL-6-induced pathobiology. A panel of human and murine mesothelioma cell lines was assayed for endogenous IL-6 production in a bioassay, and for IL-6-mRNA expression. Four out of 5 human and 5 out of 15 murine mesothelioma cell lines produced moderate to high levels of bioactive IL-6 in vitro. This result was corroborated by mRNA detection. One of the representative murine cell lines, AB22, was chosen for further in vivo studies in the murine mesothelioma model. In AB22-inoculated mice detectable serum IL-6 levels were found to precede macroscopically detectable tumour growth, clinical signs (cachexia, abdominal distension, diarrhoea) and changes in the peripheral lymphoid organs (cell depletion and functional depression). Treatment with anti-IL-6 antibody curtailed the clinical symptoms (P < 0.001), as did treatment with recombinant human (rhu) IFN alpha (P < 0.001). Neither anti-IL-6 antibody nor rhuIFN alpha had a direct growth-inhibitory effect on the AB22 mesothelioma cell line in vitro, however, in vivo rhuIFN alpha treatment of mice inoculated with AB22 cells attenuated both IL-6 mRNA expression in the tumours and serum IL-6 levels, ameliorated the depression of lymphocyte activities, and enhanced the number of tumour-infiltrating lymphocytes and macrophages. On the basis of these results it is suggested that IL-6 mediates some of these effects, directly or indirectly, and that a combination therapy of rhuIFN alpha and anti-IL-6 antibody may be an improved palliative treatment for patients with malignant mesothelioma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The text we found for this paper looks like another document, so the self-check wasn’t run.
Citations
Cites
Van Snick, J. (1990) · Annual Review of Immunology · doi:10.1146/annurev.iy.08.040190.001345 · Cited by 1,890
Evidence for the involvement of interleukin 6 in experimental cancer cachexia.
Strassmann, G., Fong, M., Kenney, J. S., & Jacob, C. O. (1992) · Journal of Clinical Investigation · doi:10.1172/jci115767 · Cited by 658
Clinical toxicity of interferons in cancer patients: a review.
Quesada, J. R., Talpaz, M., Rios, A., Kurzrock, R., & Gutterman, J. U. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.2.234 · Cited by 596
MTT colorimetric assay for testing macrophage cytotoxic activity in vitro
Ferrari, M., Fornasiero, M. C., & Isetta, A. M. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90187-z · Cited by 565
Interleukin-6 is a potent thrombopoietic factor in vivo in mice
Ishibashi, T., Kimura, H., Shikama, Y., Uchida, T., Kariyone, S., Hirano, T., Kishimoto, T., Takatsuki, F., & Akiyama, Y. (1989) · Blood · doi:10.1182/blood.v74.4.1241.1241 · Cited by 432
Interferons and other regulatory cytokines
Demaeyer, E. M., & Maeyer‐Guignard, J. D. (1988) · Medical Entomology and Zoology · Cited by 419
Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia
Klein, B., Wijdenes, J., Zhang, X., Jourdan, M., Boiron, J., Brochier, J., Liautard, J., Merlin, M., Clement, C., & Morel-Fournier, B. (1991) · Blood · doi:10.1182/blood.v78.5.1198.1198 · Cited by 418
Diffuse Malignant Mesothelioma: Prospective Evaluation of 69 Patients
CHAHINIAN, A. P., PAJAK, T. F., HOLLAND, J. F., NORTON, L., AMBINDER, R. M., & MANDEL, E. M. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-96-6-746 · Cited by 354
Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis.
Motro, B., Itin, A., Sachs, L., & Keshet, E. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3092 · Cited by 346
Interferons and other regulatory cytokines
Meager, A. (1989) · Journal of Immunological Methods · doi:10.1016/0022-1759(89)90301-3 · Cited by 304
Research works printed but not linked: 1
- Musk AW, Bowman RV, Christmas TI, Robinson BWS. Management of malignant mesothelioma. In: Henderson DW, Shilkin KB, Langlois SLP, Whitaker D, editors. Malignant mesothelioma. New York: Hemisphere; 1992. pp. 292–302. [Google Scholar]
Cited by
Advances in Malignant Mesothelioma
Robinson, B. W. S., & Lake, R. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050152 · Cited by 889
Self-citationThe role of cytokines in cancer cachexia
Argilés, J. M. A., & López-Soriano, F. J. (1999) · Medicinal Research Reviews · doi:10.1002/(sici)1098-1128(199905)19:3<223::aid-med3>3.0.co;2-n · Cited by 258
Inflammation-Based Prognostic Indices in Malignant Pleural Mesothelioma
Pinato, D. J., Mauri, F. A., Ramakrishnan, R., Wahab, L., Lloyd, T., & Sharma, R. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31823f45c1 · Cited by 150
The pivotal role of cytokines in muscle wasting during cancer
Argilés, J. M. A., Busquets, S., & López-Soriano, F. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.03.014 · Cited by 160
Nakano, T., Chahinian, A. P., Shinjyo, M., Tonomura, A., Miyake, M., Togawa, N., Ninomiya, K., & Higashino, K. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.150 · Cited by 122
Interleukin-6 Induces Both Cell Growth and VEGF Production in Malignant Mesotheliomas
Adachi, Y., Aoki, C., Yoshio‐Hoshino, N., Takayama, K., Curiel, D. T., & Nishimoto, N. (2006) · International Journal of Cancer · doi:10.1002/ijc.22006 · Cited by 115
The Pathologies of Bovine Viral Diarrhea Virus Infection
Bielefeldt‐Ohmann, H. (1995) · Veterinary Clinics of North America Food Animal Practice · doi:10.1016/s0749-0720(15)30461-8 · Cited by 83
Self-citationCancer cachexia: A therapeutic approach
Argilés, J. M. A., Meijsing, S. H., Pallarés‐Trujillo, J., Guirao, X., & López-Soriano, F. J. (2000) · Medicinal Research Reviews · doi:10.1002/1098-1128(200101)21:1<83::aid-med4>3.0.co;2-1 · Cited by 78
Cancer as a Proinflammatory Environment: Metastasis and Cachexia
Neto, N. I. P., Carnier, J., Oyama, L. M., Otoch, J. P., de Alcântara, P. S. M., Tokeshi, F., & do Nascimento, C. M. O. (2015) · Mediators of Inflammation · doi:10.1155/2015/791060 · Cited by 75
Cytokines as Mediators and Targets for Cancer Cachexia
Argilés, J. M. A., Busquets, S., & López-Soriano, F. J. (2006) · Cancer treatment and research · doi:10.1007/0-387-26283-0_9 · Cited by 67
Deliberately provoking local inflammation drives tumors to become their own protective vaccine site
Jackaman, C., Lew, A. M., Zhan, Y., Allan, J. E., Koloska, B., Graham, P. T., Robinson, B. W. S., & Nelson, D. J. (2008) · International Immunology · doi:10.1093/intimm/dxn104 · Cited by 65
Self-citationOrengo, A. M., Spoletini, L., Procopio, A. D., Favoni, R. E., de Cupis, A., Ardizzoni, A., Castagneto, B., Ribotta, M. G. Y., Pg, B., Ferrini, S., et al. (1999) · European Respiratory Journal · doi:10.1183/09031936.99.13352799 · Cited by 61
Advances in malignant peritoneal mesothelioma
Cao, S., Shi, J., Cao, J., Shen, J., Hu, J., Che, D., Pan, B., Zhang, J., He, X., Ding, D., et al. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-2029-1 · Cited by 55
CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
Magkouta, S., Vaitsi, P. C., Pappas, A., Iliopoulou, M. P., Kosti, C., Psarra, K., & Kalomenidis, I. (2021) · Cancers · doi:10.3390/cancers13112546 · Cited by 56
The “Trojan Horse” Approach to Tumor Immunotherapy: Targeting the Tumor Microenvironment
Nelson, D. J., Fisher, S. A., & Robinson, B. W. S. (2014) · Journal of Immunology Research · doi:10.1155/2014/789069 · Cited by 61
Self-citationHesdorffer, M. E., Chabot, J., DeRosa, C. M., & Taub, R. N. (2008) · Current Treatment Options in Oncology · doi:10.1007/s11864-008-0072-2 · Cited by 43
Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity
Veltman, J. D., Lambers, M. E. H., van Nimwegen, M., de Jong, S., Hendriks, R. W., Hoogsteden, H. C., Aerts, J. G. J. V., & Hegmans, J. P. J. J. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/798467 · Cited by 41
Robinson, C., Callow, M. G., Stevenson, S., Scott, B., Robinson, B. W. S., & Lake, R. (2000) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.22.5.3930 · Cited by 42
Self-citationMezzapelle, R., Rrapaj, E., Gatti, E., Ceriotti, C., Marchis, F. D., Preti, A., Spinelli, A. E., Perani, L., Venturini, M., Valtorta, S., et al. (2016) · Scientific Reports · doi:10.1038/srep22850 · Cited by 43
The pivotal role of cytokines in muscle wasting during cancer
Argilés, J. M. A., Busquets, S., & López-Soriano, F. J. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.03.007 · Cited by 51
Fiorilla, I., Martinotti, S., Todesco, A. M., Bonsignore, G., Cavaletto, M., Patrone, M., Ranzato, E., & Audrito, V. (2023) · Cells · doi:10.3390/cells12162048 · Cited by 39
Potential for Interferon-α-Based Therapy in Mesothelioma: Assessment in a Murine Model
Bielefeldt‐Ohmann, H., FITZPATRICK, D. R., Marzo, A. L., Jarnicki, A., Musk, A. W., & Robinson, B. W. S. (1995) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1995.15.213 · Cited by 39
Self-citationSerum mesothelin and other biomarkers: what have we learned in the last decade?
Cristaudo, A., Bonotti, A., Guglielmi, G., Fallahi, P., & Foddis, R. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.10.132 · Cited by 38
Jarnicki, A., Fitzpatrick, D. R., Robinson, B. W. S., & Bielefeldt‐Ohmann, H. (1996) · Cancer Letters · doi:10.1016/0304-3835(96)04178-x · Cited by 37
Self-citationMOLECULAR PATHOBIOLOGY AND IMMUNOLOGY OF MALIGNANT MESOTHELIOMA
Bielefeldt‐Ohmann, H., Jarnicki, A., & FITZPATRICK, D. R. (1996) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199604)178:4<369::aid-path460>3.0.co;2-8 · Cited by 43
Self-citationThe role of interleukin-6 in malignant mesothelioma.
Rahim, S. N. A., Ho, G., & Coward, J. I. G. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2014.07.01 · Cited by 38
Versican modulates tumor-associated macrophage properties to stimulate mesothelioma growth
Pappas, A., Magkouta, S., Pateras, I. S., Skianis, I., Moschos, C., Vazakidou, M. E., Psarra, K., Gorgoulis, V. G., & Kalomenidis, I. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1537427 · Cited by 34
Cordier, L., Valeyrie, L., Fernandez, N. C., Opolon, P., Sabourin, J., Maubec, E., Roy, P. L., Kane, A. B., Legrand, A., Abina, A. M., et al. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700594 · Cited by 33
Control of cell cycle progression in human mesothelioma cells treated with gamma interferon
Vivo, C., Levy, F., Pilatte, Y., Fleury‐Feith, J., Chrétien, P., Monnet, I., Kheuang, L., & Jaurand, M. (2001) · Oncogene · doi:10.1038/sj.onc.1204199 · Cited by 32
Taub, R. N., Keohan, M. L., Chabot, J., Fountain, K. S., & Plitsas, M. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0046-5 · Cited by 29
Inflammation in malignant mesothelioma - friend or foe?
Linton, A., van Zandwijk, N., Reid, G., Clarke, S. J., Cao, C. Q., & Kao, S. (2012) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2225-319x.2012.10.02 · Cited by 32
Sera from patients with malignant mesothelioma can contain autoantibodies
Robinson, C., Robinson, B. W., & Lake, R. A. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00014-2 · Cited by 25
Self-citationAnticancer drugs that induce cancer-associated cachectic syndromes
Tohgo, A., Kumazawa, E., Akahane, K., Asakawa, A., & Inui, A. (2002) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2.1.121 · Cited by 24
Targeting interleukin-6 as a treatment approach for peritoneal carcinomatosis
Dadgar, N., Sherry, C., Zimmerman, J., Park, H., Lewis, C. M., Donnenberg, A. D., Zaidi, A. H., Fan, Y., Xiao, K., Bartlett, D. L., et al. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05205-8 · Cited by 20
New chemotherapeutics in malignant mesothelioma: effects on cell growth and IL-6 production
McLaren, B. R., Robinson, B. W. S., & Lake, R. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051026 · Cited by 17
Self-citationPotential for cytokine therapy of malignant mesothelioma
Fitzpatrick, D. R., Manning, L. S., Musk, A. W., Robinson, B. W. S., & Bielefeldt‐Ohmann, H. (1995) · Cancer Treatment Reviews · doi:10.1016/0305-7372(95)90004-7 · Cited by 16
Self-citationStam, Swaak, Kruit, Stoter, & Eggermont (2000) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2000.00632.x · Cited by 17
Kinetics of Host Cell Recruitment During Dissemination of Diffuse Malignant Peritoneal Mesothelioma
Miselis, N. R., Lau, B. W., Wu, Z. J., & Kane, A. B. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0048-1 · Cited by 18
Temsirolimus targets multiple hallmarks of cancer to impede mesothelioma growth in vivo
Vazakidou, M. E., Magkouta, S., Moschos, C., Psallidas, I., Pappas, A., Psarra, K., & Kalomenidis, I. (2015) · Respirology · doi:10.1111/resp.12604 · Cited by 14
Adachi, Y., Yoshio‐Hoshino, N., Aoki, C., & Nishimoto, N. (2010) · PubMed · Cited by 13
Ohnuma, T., & Holland, J. F. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-291-5_4 · Cited by 10
Emerging drugs for cancer cachexia
Argilés, J. M. A., López-Soriano, F. J., & Busquets, S. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.555 · Cited by 8
Magkouta, S., Pappas, A., Pateras, I. S., Kollintza, A., Moschos, C., Vazakidou, M., Karavana, V. N., Gorgoulis, V. G., & Kalomenidis, I. (2018) · Oncotarget · doi:10.18632/oncotarget.25004 · Cited by 8
Role of interleukin-6 (IL-6) in diagnosis of malignant pleural mesothelioma
Sawy, R. E. S. E., Okab, A. A., El-Mahdy, M., Kasb, I., & Ismail, Y. (2015) · Egyptian Journal of Chest Diseases and Tuberculosis · doi:10.1016/j.ejcdt.2014.11.005 · Cited by 5
Microenvironment and Immunology of the Human Pleural Malignant Mesothelioma
Digifico, E., Belgiovine, C., Mantovani, A., & Allavena, P. (2019) · Springer eBooks · doi:10.1007/978-3-030-16884-1_5 · Cited by 6
Yanagisawa, A., Fukaya, T., Noda, K., Kojima, H., & Shimizu, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1671503 · Cited by 2
A Case of IL-6 Producing Malignant Pleuroperitoneum Mesothelioma
Hamada, T., Tsukuya, G., Mizuno, K., Samukawa, T., & Inoue, H. (2012) · Haigan · doi:10.2482/haigan.52.290 · Cited by 1
Nishi, H., Iga, N., & Shimizu, N. (2016) · The Journal of the Japanese Association for Chest Surgery · doi:10.2995/jacsurg.30.669 · Cited by 1
Molekularbiologie und „targeted therapy“ beim Pleuramesotheliom
O'Byrne, K. J. (2006) · Springer eBooks · doi:10.1007/3-540-27329-8_11
Hartmann, K. (2010) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-7006
Topical Interferon Treatment in Malignant Pleural Mesothelioma
Kobayashi, Y., Yasuba, H., Kita, H., Yamada, T., Chiba, W., & Hitomï, S. (2008) · Haigan · doi:10.2482/haigan.48.39
Management of Pleural Effusions in Mesothelioma
Andaz, S. K., & Cameron, R. B. (2005) · Springer eBooks · doi:10.1007/0-387-28274-2_43
Metadata
- Authors
- Bielefeldt-Ohmann, H., Marzo, A. L., Himbeck, R. P., Jarnicki, A. G., Robinson, B. W. S., & Fitzpatrick, D. R.
- Affiliations
- The University of Western Australia (AU)
- Venue
- Cancer Immunology Immunotherapy
- Published
- 1995-07
- Volume
- 40
- Issue
- 4
- Pages
- 241-250
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11037711
- OpenAlex
- W1980153171
- Cited by
- 52
- References
- 39
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 1 · 2021: 1 · 2019: 1 · 2018: 3 · 2016: 2 · 2015: 4 · 2014: 2 · 2012: 3
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- UWA Profiles and Research Repository (University of Western Australia) (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
- Health Sciences › Medicine › Surgery › Intraperitoneal and Appendiceal Malignancies
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Keywords
- interleukin-6, malignant mesothelioma, interferon-alpha, anti-IL-6 antibody, IL-6 mRNA expression, cachexia, lymphocyte depletion, tumor-infiltrating lymphocytes, tumour-associated macrophages, palliative care
- MeSH terms
- Interleukin-6 Inhibitors, Animals, Base Sequence, Female, Humans, Immunotherapy, Interferon Type I, Mesothelioma, Mice, Inbred BALB C, Molecular Sequence Data, Recombinant Proteins, RNA, Messenger, Tumor Cells, Cultured, Interleukin-6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.